Indian Brachytherapy Society consensus recommendations for brachytherapy in breast cancer.

Autor: Sharma DN; Department of Radiation Oncology, AIIMS, New Delhi, India., Budrukkar A; Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India., Kumar R; Department of Radiation Oncology, AIIMS, New Delhi, India., Wadasadawala T; Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India., Sarin R; Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India., Upreti R; Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India., Binjola A; Department of Radiation Oncology, AIIMS, New Delhi, India., Mahantshetty U; Department of Radiation Oncology, Homi Bhabha Cancer Hospital and Research Centre, Visakhapatnam, India.; Department of Surgical Oncology, AIIMS, New Delhi, India., Badwe R; Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India.
Jazyk: angličtina
Zdroj: Journal of contemporary brachytherapy [J Contemp Brachytherapy] 2024 Aug; Vol. 16 (4), pp. 257-267. Date of Electronic Publication: 2024 Sep 12.
DOI: 10.5114/jcb.2024.142936
Abstrakt: Purpose: This consensus statement of Indian Brachytherapy Society (IBS) aims to generate practical and reproducible guidelines allowing for direct implementation in the Indian scenario.
Material and Methods: IBS board of directors appointed a panel of physicians with expertise in breast cancer and, in particular, breast brachytherapy, to develop a consensus statement. First, a literature review on breast brachytherapy was conducted, focusing on randomized trials, prospective studies, and multi-institutional series. Then, guidelines were drafted based on authors' consensus according to Indian scenario.
Results: IBS advocate accelerated partial breast irradiation (APBI) with brachytherapy following breast conservation surgery (BCS) for suitable groups of patients. Also, IBS recommends brachytherapy as the preferred technique for patients requiring tumor bed boost. Multi-catheter interstitial brachytherapy (MIB) is suitable in most situations, except for a large tumor to breast ratio, and type 2 oncoplasty or higher performed. For best cosmesis, IBS recommends a minimum 3-week gap between chemotherapy and APBI.
Conclusions: Brachytherapy continues to be an established technique for APBI as well as boost in appropriately selected patients with early breast cancer (EBC). As breast brachytherapy is an underutilized therapy in the Indian context, this article will hopefully encourage the readers to use its clinical potential in the suitable groups of patients.
Competing Interests: The authors declare no conflict of interest.
(Copyright © 2024 Termedia.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje